The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Antitumor activity in a randomized phase II study comparing two schedules of NKTR-102 in patients (Pts) with pretreated metastatic breast cancer (MBC).
A. Awada
Research Funding - Nektar
S. Chan
Research Funding - Nektar
G. H. M. Jerusalem
Research Funding - Nektar
R. E. Coleman
Research Funding - Nektar
M. T. Huizing
Research Funding - Nektar
A. Mehdi
Research Funding - Nektar
S. M. O'Reilly
Research Funding - Nektar (B)
J. T. Hamm
Research Funding - Nektar
P. J. Barrett-Lee
Research Funding - Nektar
V. Cocquyt
Research Funding - Nektar
K. Sideras
Research Funding - Nektar
D. E. Young
Research Funding - Nektar
M. Brown
Employment or Leadership Position - Nektar
C. Zhao
Employment or Leadership Position - Nektar
A. L. Hannah
Consultant or Advisory Role - Nektar
L. K. Masuoka
Employment or Leadership Position - Nektar
A. Garcia
Research Funding - Nektar
E. A. Perez
Research Funding - Nektar